Your browser doesn't support javascript.
loading
Multiomics Profiling Distinguishes Sebaceous Carcinoma from Benign Sebaceous Neoplasms and Provides Insight into the Genetic Evolution of Sebaceous Carcinogenesis.
Starrett, Gabriel J; Baikie, Brittany C; Stoff, Benjamin K; Grossniklaus, Hans E; Van Buren, Inga; Berry, Elizabeth G; Novoa, Roberto A; Rieger, Kerri E; Sarin, Kavita Y; Lynch, Charles F; Royer, Michael C; Piaskowski, Mary L; Brownell, Isaac; Chu, Emily Y; Godse, Rama; Chen, Suephy C; Yu, Kelly J; Goldstein, Alisa M; Engels, Eric A; Sargen, Michael R.
Affiliation
  • Starrett GJ; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Baikie BC; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Stoff BK; Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.
  • Grossniklaus HE; Department of Ophthalmology, Emory University School of Medicine, Emory University, Atlanta, Georgia.
  • Van Buren I; Dignity Health St. Joseph's Medical Center, Stockton, California.
  • Berry EG; Department of Dermatology and Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon.
  • Novoa RA; Department of Dermatology, Stanford University School of Medicine, Stanford, California.
  • Rieger KE; Department of Pathology, Stanford University School of Medicine, Stanford, California.
  • Sarin KY; Department of Dermatology, Stanford University School of Medicine, Stanford, California.
  • Lynch CF; Department of Pathology, Stanford University School of Medicine, Stanford, California.
  • Royer MC; Department of Dermatology, Stanford University School of Medicine, Stanford, California.
  • Piaskowski ML; Iowa Cancer Registry, Department of Epidemiology, The University of Iowa, Iowa City, Iowa.
  • Brownell I; Division of Dermatopathology, The Joint Pathology Center, Silver Spring, Maryland.
  • Chu EY; Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Godse R; Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.
  • Chen SC; Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
  • Yu KJ; Department of Internal Medicine, Pennsylvania Hospital, Philadelphia, Pennsylvania.
  • Goldstein AM; Duke Dermatology, Duke University School of Medicine, Durham, North Carolina.
  • Engels EA; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
  • Sargen MR; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
Clin Cancer Res ; : OF1-OF13, 2024 Sep 17.
Article in En | MEDLINE | ID: mdl-39287419
ABSTRACT

PURPOSE:

Sebaceous carcinoma is the third most common nonkeratinocyte skin cancer in the United States with 1,000 cases per year. The clinicopathologic features of sebaceous carcinoma and benign sebaceous neoplasms (adenomas, sebaceomas) can overlap, highlighting the need for molecular biomarkers to improve classification. This study describes the genomic and transcriptomic landscape of sebaceous neoplasms in order to understand tumor etiology and biomarkers relevant for diagnosis and treatment. EXPERIMENTAL

DESIGN:

We performed whole-genome sequencing (WGS) and whole-transcriptome sequencing (WTS) of sebaceous neoplasms from six academic and two federal healthcare facilities in the United States diagnosed between January 1, 1999, and December 31, 2021.

RESULTS:

We evaluated 98 sebaceous neoplasms 64 tumors (32 adenomas, 2 sebaceomas, 5 atypical sebaceous neoplasms, 25 carcinomas) had sufficient material for WGS, 96 tumors (42 adenomas, 11 sebaceomas, 8 atypical sebaceous neoplasms, 35 carcinomas) had sufficient material for WTS, and 62 tumors (31 adenomas, 2 sebaceomas, 5 atypical sebaceous neoplasms, 24 carcinomas) had sufficient material for combined WGS and WTS. Overall, we found decreased cholesterol biosynthesis and increased TP53 mutations, copy number gains (chromosome 6, 8q, and/or 18), and tumor mutation burden-high (>10 mutations/MB) in carcinomas compared to adenomas. Although diminished compared to adenomas, most carcinomas still had higher cholesterol biosynthesis than nonmalignant skin. Multiomics profiling also supported a precancerous model of tumor evolution with sebaceomas and atypical sebaceous neoplasms being likely intermediate lesions.

CONCLUSIONS:

The study findings highlight key diagnostic biomarkers for sebaceous carcinoma and suggest that immunotherapy and modulation of cholesterol biosynthesis could be effective treatment strategies.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2024 Document type: Article Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2024 Document type: Article Country of publication: United States